TABLE 3.
Summary of CD4+ T-cell VP1/2-specific 20-mer peptide sequences identified by cultured IFN-γ ELISPOT assays of cells from B19-seropositive remotely infected individuals (OR1-8)a
| B19 region | CD4+ T-cell-restricted peptide sequence | Peptide no. | Response of patient to peptide
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| OR1 | OR2 | OR3 | OR4 | OR6 | OR7 | OR8 | |||
| VP1U | MSKESGKWWESDDKFAKAVY | 1.1 | − | − | − | − | − | − | + |
| VP1U | LKDHYNISLDNPLENPSSLF | 1.5 | − | − | − | − | − | − | + |
| VP1U | DLVARIKNNLKNSPDLYSHH | 1.7 | − | − | − | − | + | + | − |
| VP1U | RIHDFRYSQLAKLGINPYTH | 3.2 | − | − | − | − | − | + | − |
| VP1U | WTVADEELLKNIKNETGFQA | 3.4 | + | − | − | − | − | − | − |
| VP1U | QVVKDYFTLKGAAAPVAHFQ | 3.6 | − | − | − | + | − | − | − |
| VP1/2 | GGGGSNPVKSMWSEGATFSA | 4.4 | − | − | + | − | − | − | − |
| VP1/2 | FLIPYDPEHHYKVFSPAASS | 4.7 | − | − | + | − | − | + | + |
| VP1/2 | YKVFSPAASSCHNASGKEAK | 5.1 | + | − | − | − | − | − | − |
| VP1/2 | STPWRYLDFNALNLFFSPLE | 5.4 | − | − | − | − | + | − | + |
| VP1/2 | ALNLFFSPLEFQHLIENYGS | 5.5 | + | + | − | − | − | − | − |
| VP1/2 | FQHLIENYGSIAPDALTVTI | 5.6 | − | − | + | − | − | − | − |
| VP1/2 | LPIWVYFPPQYAYLTVGDVN | 6.6 | + | + | − | − | − | − | − |
| VP1/2 | YAYLTVGDVNTQGISGDSKK | 6.7 | + | − | − | − | − | − | − |
| VP1/2 | LASEESAFYVLEHSSFQLLG | 7.2 | + | + | + | − | + | + | + |
| VP1/2 | LEHSSFQLLGTGGTATMYSK | 7.3 | − | + | − | − | − | − | + |
| VP1/2 | TGGTATMSYKFPPVPPENLE | 7.4 | + | − | − | − | − | − | − |
| VP1/2 | PDTLGGDPKFRSLTHEDHAI | 8.1 | − | − | − | − | − | − | + |
| VP1/2 | KYVPGINAISHGQTTYGNAE | 9.2 | − | − | − | − | − | − | + |
| VP1/2 | LQGLNMHTYFPNKGTQQYTD | 9.6 | − | − | − | − | − | − | + |
| VP1/2 | VWNRRALHYESQLWSKIPNL | 10.2 | − | + | − | + | − | − | − |
| VP1/2 | PQIFLKILPQSGPIGGIKSM | 10.6 | − | − | − | − | − | + | − |
| VP1/2 | GIMTVTMTFKLGPRKATGRW | 11.2 | − | − | − | − | − | − | + |
a
A positive response is taken as being greater than the value for the negative control (medium alone) plus 2 standard deviations. Positive responses were then confirmed by stimulating PBMCs with the identified 20-mer peptides and testing the T-cell lines in an ICS assay. Boldface type identifies the peptide sequence found to be restricted by HLA DRB1*1501.